Sign up to save your podcasts
Or
Share The use of Immunotherapy in unresectable Hepatocellular Carcinoma (HCC)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The use of Immunotherapy in unresectable Hepatocellular Carcinoma (HCC)
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.
Topics also include:
• Efficacy and safety of IO and IO combinations in HCC
• How to select between the two 1st-line IO-based treatment options based on clinical factors
• Future treatment in unresectable HCC
Clinical Takeaways
• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary
• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
View all episodes
By Oncology Brothers
4.8
3939 ratings
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.
Topics also include:
• Efficacy and safety of IO and IO combinations in HCC
• How to select between the two 1st-line IO-based treatment options based on clinical factors
• Future treatment in unresectable HCC
Clinical Takeaways
• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary
• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
505 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,116 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
362 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners